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Safety, Efﬁcacy, and Favorability of Utilizing
Levetiracetam for Busulfan-Induced Seizure Prophylaxis
in Pediatric Patients Undergoing Hematopoietic Cell
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Intravenous Busulfan is a common conditioning agent for
children undergoing HCT. A potential adverse effect of
Busulfan is seizures thus anti-convulsant prophylaxis is
standard. Phenytoin is no longer preferred given its potent
inhibition of cytochrome P450 hepatic enzymes and benzo-
diazepenes also have signiﬁcant side effects that may
prohibit use. One promising alternative is Levetiracetam,
a second-generation antiepileptic with lower side effect
proﬁle and limited drug interactions including Busulfan. We
evaluated the incidence, safety, and efﬁcacy of Levetiracetam
for short-term anti-seizure prophylaxis in pediatric patients
receiving Busulfan as part of HCT conditioning.
Retrospective chart review was done on patients who
received Busulfan prior to HCT from 2007 to 2012. A total of
95 patients with a malignant or non-malignant diseases, and
autologous or allogeneic donors were included. First line
anti-convulsant therapy was Lorazepam (0.2mg/kg IV/PO
every 6 hours). Those patients who had documented or new
adverse reactions to Lorazepam, who were already taking
Levetiracetam, or who had increased baseline risk factors for
seizures, received alternative prophylaxis with Levetir-
acetam (10-15mg/kg IV/PO every 6 hours).
Of the 95 patients who received Busulfan-based condi-
tioning, 33 (35%) received Levetiracetam instead of institu-
tional standard Lorazepam. Thirteen of the 33 patients (30%)
were either previously on Levetiracetam due to a prior
seizure or received it preemptively due to increased risk of
seizures. Twenty-three of these 33 patients (70%) were
switched to Levetiracetam due to prior (n¼10) or develop-
ment of new (n¼13) adverse reaction to Lorazepam. Leve-
tiracetam was extremely well tolerated with no adverse
events. There were no Busulfan-induced seizures or neuro-
toxicity in either cohort.
Our ﬁndings indicate that one-third of analyzed patients
required Levetiracetam instead of the institutional standard
of Lorazepam for anti-convulsant prophylaxis during
Busulfan administration. Overall, Levetiracetam was efﬁca-
cious in preventing Busulfan-induced seizures with no
documented side effects, whereas Lorazepamwas not as well
tolerated. Notably, a signiﬁcant number of patients devel-
oped adverse reactions to Lorazepam mid-chemotherapy
creating interruptive and unpleasant side effects, the most
common being over-sedation, irritability and hyperactivity.
Practically and economically, Levetiracetam is also attractive
given its less frequent dosing and available low-cost generic
formulation.
Current practice is to use benzodiazepines to prevent
Busulfan-induced seizures. Our ﬁndings substantiate earlydata showing that not only is Levetiracetam safe, effective,
and feasible in preventing Busulfan-induced seizures during
pediatric HCT, but also may actually be favorable due to
lower side effect proﬁle and ease of administration.291
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Introduction: Toxicity associated with the hematopoietic
stem cell transplant (HSCT) process commonly results in
a need for critical care resources. Identifying biomarkers
associated with critical illness in HSCT patients may improve
outcomes. Brain natriuretic peptide (BNP) has become
a useful marker of cardiopulmonary disease inmany settings.
The value of BNP levels early in the HSCT process in children
is largely unknown.
Hypothesis: Children with elevated BNP levels during the
ﬁrst 14 days after HSCT will be at higher risk for toxicity and
more likely to require critical care resources during the ﬁrst
100 days after HSCT.
Methods: A multicenter, prospective study recruited pedi-
atric allogeneic HSCT patients from 5 tertiary care centers.
BNP levels were assessed at the start of conditioning, at Day-
1, and at Days +1, +7, +14, +21, +28, and +100 after HSCT.
Patients were followed for 100 days after HSCT. Outcome
variables included the need for inotropic support, supple-
mental oxygen, PICU admission and survival. Odds ratios
were determined to assess the relationship of elevated BNP
levels with these outcomes. An elevated BNP level was
deﬁned a priori as > 100 pg/mL.
Results: Fifty one patients were enrolled. The median age
was 12 years (IQR 6-15). There were 29 males. Forty patients
(78%) were transplanted for malignant diseases. Thirty eight
of the 51 patients (75%) had at least 1 BNP level> 100 within
14 days of transplant. The median BNP levels were 21, 28.5,
65, 56, 105, 55, 36 and 24 pg/mL at baseline, Day-1, +1, +7,
+14, +21, +28 and +100 of HSCT respectively. A BNP level >
100 was associated with a need for oxygen (P ¼ .003) and
PICU admission (P ¼ .02), but not inotropic support. Overall,
23 of the 51 patients (45%) required oxygen. Of these 23, all
but one (96%) had at least one BNP level > 100 during the
ﬁrst 14 days post HSCT. In contrast, only 16 of the 28 patients
(57%) who did not require oxygen had a BNP level > 100
during that time frame (Odds ratio 16.5, 95% CI (1.9 e 140.1)).
Nineteen of the 51 patients (37%) required admission to the
PICU. Of these 19, 18 patients (95%) had at least one BNP >
100 within the ﬁrst 14 days of HSCT. In contrast, only 20 of
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had a BNP level > 100 during that time frame (Odds ratio
10.8, 95% CI (1.3 e 91.5)). Six patients (12%) died due to
transplant related mortality in the ﬁrst 100 days; 5 of these
(83%) had a BNP level >100 during the ﬁrst 14 days.
Conclusions: BNP levels peaked at Day +14 after allogeneic
HSCT in this study. Children who required critical care
resources (oxygen and PICU admission) almost invariably
demonstrated an elevated BNP during the ﬁrst 14 days after
HSCT. This information may be useful clinically and for risk
stratiﬁcation in studies of pediatric HSCT patients. The
etiology of the rise in BNP requires further study.Table 1
Patient Characteristics (n¼32)
Characteristic N (%)






Matched sibling 15 (47)
Matched unrelated 13 (41)
Mismatched unrelated / haploidentical / cord blood 4 (12)
Conditioning regimen
Myeloablative 19 (59)
Reduced intensity 13 (41)
Acute GVHD 14 (44)
Chronic GVHD 27 (84)
Patients on2 immunosuppressors at RSV diagnosis 21 (66)
Clinical syndrome
Upper tract infection 16 (50)
Pneumonia 16 (50)
Median days from transplant to RSV infection
(interquartile range)
382 (241 to 1049)292
Research qPCR Method for Engraftment Monitoring: A
6-Year Review of Proﬁciency Testing Results
Ian J. McLaughlin, Christopher L. Sigua, Douglas A. Bost. Quest
Diagnostics
A total of 40 samples were tested from 11 proﬁciency surveys
from 2006 through 2012 using samples from the American
Society for Histocompatibility and Immunogenetics (ASHI)
and the Post-SCT Chimerism Monitoring Programme of the
United Kingdom National External Quality Assessment
Schemes (UK NEQAS) for Leucocyte Immunophenotyping.
Sample percentage breakdown by reported means for the 39
ASHI samples is as follows: 3 did not consist of target cells
(0% samples), 5 consisted of target percentages from 5.7 to
22.28%, 8 consisted of target percentages from 26.2 to 49.2%,
20 consisted of target percentages from 51.2 to 95.93%, and 3
consisted only of target cells (100% samples). The single UK
NEQAS sample reported a median percentage of 94.70%.
Thirty-two of the forty samples (80%) consisted of target
percentages above 25%.
All 40 samples tested to date have received passing results
with our research qPCR method. For the three 0% samples
from 3 separate surveys, our qPCRmethod gave a result of 0%
for each sample while the STR PCR method gave a result
other than 0% in 14 instances. For the three 100% samples
from 3 separate surveys, our qPCR method gave a result of
100% for each samplewhile the STR PCRmethod gave a result
other than 100% in 10 instances.
It is not until recently (2012), that more than 1 or 2 testing
sites in the ASHI proﬁciency testing program have used
a qPCRmethod. The last ASHI survey of 2012 and the ﬁrst and
current UK NEQAS trial of the 2012-2013 schedule both
included 4 sites using qPCR. The qPCR method is a valuable
tool capable of studying chimerism far below the levels
attained by STR PCR (e.g. microchimerism < 1%). As the
number of sites using qPCR potentially increases, proﬁciency
testing organizations should include lower percentage
samples in order to adequately test the lower sensitivities
attainable with the qPCR method.
While ASHI participation began in 2006, it was not until 2010
that speciﬁc mention of our qPCR approach appeared in the
summary report. In the latest ASHI survey (2012 EMO-2), it
was recognized in the summary report that both conven-
tional (STR PCR) and qPCR assays can be used successfully
based on the comparable performance of the methods. Six
years of proﬁciency testing participation lends concrete
evidence that our research qPCR method is a viable alter-
native to the STR PCR approach offering unmatched sensi-
tivity while maintaining high accuracy and reproducibility
with low to high percentage samples.293
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Background: Respiratory syncytial virus (RSV) is a poten-
tially life threatening infection in allogeneic stem cell
transplant (Allo) recipients. Viral respiratory tract infections
have also been implicated in bronchiolitis obliterans (BO)
and other post Allo non-infectious pulmonary complications
(NIPCs). Since 2000, we have treated RSV infections in Allo
patients (pts) in a standardized manner with pre-established
criteria. We sought to determine survival of such uniformly
treated pts and to ascertain their risk of subsequent NIPCs.
Methods: Allo pts were systematically tested for RSV if they
presented with evidence of lower respiratory tract infection
or upper respiratory tract symptoms and predeﬁned risk
factors for RSV pneumonia. Pts received inhaled ribavirin 2 g
q8h  15 doses and standard IVIG 500 mg/kg/day  4 days
(d) if they exhibited any of the following features: 1) neu-
tropenia, 2) pneumonia, 3) active treatment for GVHD. Data
from 1/00 to 6/12 were collected retrospectively and ana-
lysed on an “intent-to-treat” basis.
Results: We present the ﬁrst 32 pts; their characteristics are
shown in Table 1. Of those with RSV pneumonia, one died 17
d after diagnosis (case fatality rate 6.3%; 95%CI: 0.2-30.2%)
after receiving partial treatment in the context of palliative
care for relapsed leukemia. In total, 13 pts died (40.6%; 95%
CI: 23.7-59.4%). Causes of death other than RSV included
GVHD (n¼4), relapse (n¼5), fungal and bacterial
pneumonia (n¼2), ARDS (n¼1) and other (n¼1). Median OS
from RSV infection was 53 months (m) (95%CI: 22 m-not
reached). Four pts had been diagnosed with BO 9 to 251
d prior to RSV. Among the 28 at risk for developing BO, the
incidence was 0% (95%CI: 0-12.3%). One was diagnosed
with cryptogenic organizing pneumonia 36 d after RSV
(3.4%; 95%CI: 0-18.3%).
